^
No biomarker
Leiomyosarcoma
trabectedin
Sensitive
:
A1
No biomarker
Leiomyosarcoma
eribulin mesylate
Sensitive
:
A2
No biomarker
Leiomyosarcoma
PTC596
Sensitive
:
B
Chr amplification(4)(q22.1)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(3)(q14.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(11)(q25)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(2)(q14.1)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(2)(p12)
Leiomyosarcoma
eribulin mesylate
Sensitive
:
C3
Chr del(1)(q44)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(8)(q13.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(8)(q22.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(13)(q13.3)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(20)(p12.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(4)(q26)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
ATRX mutation
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
TP53 mutation
Leiomyosarcoma
eribulin mesylate
Sensitive
:
C3
ATRX mutation
Leiomyosarcoma
dacarbazine
Resistant
:
C3
TP53 mutation
Leiomyosarcoma
dacarbazine
Resistant
:
C3
PLK4 expression
Leiomyosarcoma
CFI-400945
Sensitive
:
D
CSPG4 overexpression
Leiomyosarcoma
CSPG4.TNK
Sensitive
:
D
HAT1 overexpression
Leiomyosarcoma
pazopanib
Resistant
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our